Ketanest (Esketamine Hydrochloride)

Esketamine, the active component of Ketanest, blocks the NMDA receptor in the central nervous system. By inhibiting this excitatory pathway, it disrupts normal neuronal signaling, leading to dissociative anesthesia and analgesia. The drug also modulates opioid and monoamine systems, which contributes to its overall anesthetic effect.

The specific dose of Ketanest is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and the intended procedure. Healthcare professionals calculate the appropriate amount and route (intramuscular or intravenous) to achieve the desired anesthetic depth.

Safety data for Ketanest in pregnancy and lactation are limited. It is generally classified as contraindicated or used only when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case individually and consider alternative anesthetic options when possible.

To order Ketanest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with traditional intravenous anesthetics such as propofol, Ketanest (esketamine) offers dissociative anesthesia with less respiratory depression but may cause higher blood pressure and emergence phenomena. Its rapid onset and analgesic properties make it valuable for procedures where preserving airway reflexes is advantageous.

Ketanest should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the vial from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and inspect for particulate matter before administration.

Ketanest is administered by a qualified healthcare professional via intramuscular or intravenous injection. The route, injection speed, and total dose are tailored to the patient’s clinical status and the procedural requirements, with continuous monitoring of vital signs throughout the anesthetic period.

The most serious risks include respiratory depression, severe hypertension or hypertensive crisis, emergence reactions such as agitation or hallucinations, and rare allergic responses. Prompt recognition and management of these events are essential, and facilities should be equipped for airway support and cardiovascular monitoring.

Ketanest is contraindicated in patients with known hypersensitivity to esketamine or any component of the formulation, those with uncontrolled hypertension, severe cardiovascular disease, or a history of psychosis. Caution is also advised for individuals taking monoamine oxidase inhibitors or other NMDA antagonists.